Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 30, 2014
 
Register | Sign in
Home Page > Videos > Old Structures - New Targets for Antivirulence Salicylidene Acylhydrazide Compounds
  Videos

Return

Old Structures - New Targets for Antivirulence Salicylidene Acylhydrazide Compounds
Select Biosciences Ltd

Salicylidene acylhydrazide compounds have been demonstrated to perturb the function of the type three secretion of many important human pathogens including Escherichia coli O157 and Yersinia pseudotuberculosis. The actual protein targets of these compounds had, to this date, been unknown. In this work we present the identification and verification of three such protein targets. Each protein was identified using a combination of affinity chromatography and Far-western analyses followed by phenotypic testing of defined bacterial mutants using in vitro and in vivo assays. , , The structure of the target protein with the greatest effect on virulence in Yersinia pseudotuberculosis was solved in 3 forms by X-ray crystallography. In combination with studies of inactive mutants, and conformational changes in the protein caused by redox active state, we present localised regions likely to bind to the drug. Work is under way to solve the structure of protein and compound that will permit refinement of the salicylidene acylhydrazides with the long-term goal of developing clinically-useable drugs.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Accelerating Spirocyclic Polyketide Synthesis
Powerful flow chemistry techniques used for complex multi-stage synthesis of spirocyclic polyketides.
MS Drug Candidate Shows Promise for Ulcerative Colitis
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.
First Atlas of Body Clock Gene Expression in Mammals Informs Timing of Drug Delivery
Penn Medicine study has implications for 100 top-selling US drugs, half of which target daily-oscillating genes.
New Technique has Profound Implications for Drug Development
The method, developed by Scripps Research Institute chemists, expands options for making pure batches of ‘one-handed’ molecules.
Blood Test Developed to Diagnose Early Onset Alzheimer’s Disease
New blood-test could predict a person’s risk of developing AD much earlier than is currently possible.
Tea and Citrus Products Could Lower Ovarian Cancer Risk
New UEA research finds that women who consume foods containing flavonols and flavanones significantly decrease their risk of developing epithelial ovarian cancer.
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
Heart Drug May Help Treat ALS, Mouse Study Shows
Scientists blocked the enzyme in ALS astrocytes using digoxin, a medication used in the treatment of heart failure.
Team Discovers How Microbes Build a Powerful Antibiotic
Researchers discovery opens up new avenues of research into thousands of similar molecules.
LLNL, UC Davis Partner to Personalize Cancer Medications
With a $7.8 million, five-year grant from the NIH researchers are utilizing accelerator mass spectrometry for cancer research.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv